Proactive Investors - Run By Investors For Investors

Genedrive revenues rise as it waits for EU approval

Genedrive’s HCV assay provides on-the-spot results in just 90 minutes direct from a very small plasma sample.
picture of Genedrive device
Test results come back within 90 minutes

Genedrive PLC (LON:GDR) boosted revenues by 45% in its latest half year as it prepares for the launch of its hepatitis C test once it gets an award of CE mark.

The receipt of CE IVD certification under the EU Medical Devices Directive would green-light the commercialisation of the product in the European Union.

Genedrive’s HCV assay provides on-the-spot results in just 90 minutes direct from a very small plasma sample.

Revenues in the half year to December rose to £2.9mln (£2mln), with sales related to Genedrive up 71% to £1.2mln.

Investment in the hand-held device, however, meant losses of £2.7mln in the year. The company had cash at the period-end of £5.7mln.

David Budd, Genedrive’s chief executive, said: "The recent period has seen genedrive plc continue to focus on the significant opportunity we see in molecular diagnostics with our rapid, point of need Genedrive system.

“In Hepatitis C, we are making very positive progress. Our recent application for CE certification positions us well to be first to market with a decentralised point of need HCV qualitative test which would enable real-time treatment and management of chronic HCV patients with the new generation of direct acting antivirals. 

"Despite the difficulties in accessing the full potential of the Genedrive system thus far through the MTB/RIF launch, the Board remains confident of the business strategy. “

View full GDR profile View Profile

Genedrive PLC Timeline

Related Articles

July 27 2017
Regulatory sign-off will fire the starting pistol on the commercial launch in Europe
blood cells
October 04 2017
The two parts of the business - the commercial arm and research function - appear to be firing on all cylinders
Novogen: Access latest PPT from Proactive's CEO Sessions
April 13 2017
Dr James Garner talked clinical-stage programs with investors.

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use